Literature DB >> 9324629

[Microcirculation and hemostasis in inflammatory processes. Modulation by administration of physiologic protease inhibitors as a therapeutic approach].

B Leithäuser1, F R Matthias.   

Abstract

BACKGROUND: The course of an inflammatory process is based upon complex interactions between the vessel wall and the humoral or cellular compounds of the vascular content as a consequence of a defense reaction. There are no substantial differences between the pathophysiology of local or of whole body inflammation on the molecular and cellular level. Sepsis, which is clinically regarded as a systemic inflammatory process requires the broad therapeutical spectrum of nowaday intensive care medicine, but still has a high mortality. The pathophysiology and clinical examples for both systemic and local inflammatory reactions are presented in this paper. Thereby, similar interactions between the vascular endothelium, the mediator systems to which the hemostatic system has to be considered as a part of, and the microcirculation remain in the foreground at first. Based on that, the use of polyvalent protease inhibitors in the therapy of local or systemic inflammatory reactions of different origin will be discussed. The spotlight falls on physiological inhibitors of the hemostatic and complement system, antithrombin III and C1-esterase inhibitor, which may have a regulatory function within these systems because of their multiple targets.
CONCLUSION: The possibility of an adjuvant therapy of local or generalized inflammatory processes with physiologic protease inhibitors seems to be very promising. Nevertheless, at yet the substantial mechanisms of action are not fully understood.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9324629     DOI: 10.1007/BF03042575

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  35 in total

Review 1.  Vascular effects of thrombin.

Authors:  E Glusa
Journal:  Semin Thromb Hemost       Date:  1992       Impact factor: 4.180

Review 2.  Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C.

Authors:  C T Esmon; F B Taylor; T R Snow
Journal:  Thromb Haemost       Date:  1991-07-12       Impact factor: 5.249

Review 3.  New therapeutic approaches in sepsis: a critical review.

Authors:  L A Eidelman; R Pizov; C L Sprung
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440

Review 4.  Biochemistry and pathophysiology of human C1 inhibitor: current issues.

Authors:  M Schapira; A de Agostini; J A Schifferli; R W Colman
Journal:  Complement       Date:  1985

5.  Round table conference on clinical trials for the treatment of sepsis.

Authors:  W J Sibbald; J L Vincent
Journal:  Crit Care Med       Date:  1995-02       Impact factor: 7.598

6.  Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III.

Authors:  M Uchiba; K Okajima; K Murakami; H Okabe; K Takatsuki
Journal:  Am J Physiol       Date:  1996-06

7.  Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle.

Authors:  M Pemberton; G Anderson; V Vĕtvicka; D E Justus; G D Ross
Journal:  J Immunol       Date:  1993-06-01       Impact factor: 5.422

8.  Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis.

Authors:  G Dickneite; E P Pâques
Journal:  Thromb Haemost       Date:  1993-02-01       Impact factor: 5.249

9.  Effects of leukocyte activation on capillary hemodynamics in skeletal muscle.

Authors:  A G Harris; T C Skalak
Journal:  Am J Physiol       Date:  1993-03

Review 10.  Coagulation inhibitor substitution during sepsis.

Authors:  F Fourrier; M Jourdain; A Tournois; C Caron; J Goudemand; C Chopin
Journal:  Intensive Care Med       Date:  1995-11       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.